Clinical trial NCT02996773: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Official title: A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia
Lymphoma,Non-Hodgkin
Lymphoma, Hodgkin
Lymphoma, Follicular
Marginal Zone Lymphoma
Large Cell Lymphoma
Mantle-Cell Lymphoma
Gray Zone Lymphoma
Burkitt Lymphoma
High Risk Undifferentiated Acute Leukemia
Keywords: high-risk malignancies
Lymphoma
Haploidentical
Bone Marrow Transplant (BMT)
Post-transplant
myeloablative (MAC)
reduced intensity conditioning (RIC)
haploidentical hematopoietic cell transplantation (HHCT)
Leukemia
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2016-12-19
Enrollment: 50
Sex: ALL
Minimum age (years): 4
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of progressively substituting day +3 and +4 post-transplant cyclophosphamide (PT-CY) with post-transplant bendamustine (PT-BEN) in myeloablative (MAC) haploidentical hematopoietic cell transplantation (HHCT) for patients with hematological malignancies.

The goal of the Phase 1 component of the study is to evaluate the safety of progressively substituting post-transplant cyclophosphamide (PT-CY) given on Days +3 and +4 with bendamustine (PT-BEN). The Phase I component of the study has been completed.

The Phase Ib component of the study will continue to evaluate the safety and efficacy of subjects who receive PT-BEN on Days +3 and +4 at the maximum tolerated dose determined by Phase I. The Phase Ib component of the study has been completed.

Approximately, 18-36 subjects will be treated as part of Phase I and 15 as part of Phase Ib. Approximately 18 subjects will be used as controls, subjects that receive no PET-BEN, for direct comparison. Total, approximately 38-56 treatment and control patients and 38-56 donor subjects will be enrolled.

Detailed description: This study will follow the standard-of-care bone marrow transplant (BMT), with the only exception being to progressively substitute post-transplant cyclophosphamide (on Days +3 and +4 after BMT) with bendamustine. Six dose levels were planned for the Phase I component of the study, consisting of a combination of sequentially reduced doses of cyclophosphamide (PT-CY) and increased doses of bendamustine (PT-BEN) initially on Day +4 after BMT, followed by the same sequential reduction and increase on Day +3. An interim analysis was performed after cohort 3 was completed in Phase I and included a preliminary comparison between treatment and control groups. Phase Ib will evaluate patients treated with PT-CY on day +3 and PT-BEN on day +4.

Control patients will be patients that have declined to participate in the main trial but will receive haploidentical BMT with the current standard of two days of PT-CY (and no PT-BEN) and will be consented for the immune monitoring studies only.

Eligibility criteria: Inclusion Criteria:

* Be willing and able to provide written consent/assent for the trial.
* Diagnosed with one of the following high-risk malignancies, which require hematopoietic cell transplantation (HCT) but do not have an available Human Leukocyte Antigen (HLA)-matched related or unrelated donor or acceptable cord blood
* High risk acute lymphoblastic leukemia (ALL) in 1st complete remission (CR1) or greater
* High risk acute myelogenous leukemia (AML) in CR1 or greater
* High risk undifferentiated acute leukemia
* High risk myelodysplastic syndrome (MDS)
* Chronic Myelogenous Leukemia (CML) failing or intolerant to Tyrosine Kinase Inhibitors (TKIs) or in accelerated, blastic phase, or in second or subsequent chronic phase
* Lymphoma, (Hodgkin and Non-Hodgkins Lymphoma including marginal zone, follicular lymphoma, chemotherapy-sensitive large-cell, mantle cell lymphoma, gray zone, and Burkitt's lymphoma in remission).
* At least one haploidentical related donor is available for bone marrow harvest.
* Molecular based HLA typing for the HLA-A, -B, -Cw, beta chain (-DRB1) and - DQ Beta 1 Locus (DQB1loci) to the resolution is needed to establish haploidentity.
* A minimum match of 5/10 is required.
* No availability of an 8/8 HLA-matched related or unrelated donor or clinical urgency for transplant (e.g., needed within 4-8 weeks) at which time an acceptable unrelated donor will not be available.

Exclusion Criteria:

* Refractory acute leukemia (\>5% blasts) or progressive disease
* Untreated or progressive central nervous system leukemia
* Refractory to chemotherapy lymphoma
* Co-morbidities precluding patient's ability to tolerate BMT
* Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) \> 5 x upper limit of normal (ULN)
* Bilirubin \> 2 x ULN
* Creatinine greater than \>2 x ULN for age or creatinine clearance/glomerular filtration rate (GFR) \<40 ml/min/1.73m2
* Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) \< 40% of normal or O2 Sat \<92%
* Cardiac: left ventricular ejection fraction \<35%
* Active infection at time of hospital admission of Haplo BMT
* Documented fungal infection or highly suspected and receiving treatment for presumed fungal infection within 3 months of BMT
* HIV positive
* Karnofsky score (adults) \< 60% or Lansky score \< 50% (pediatrics).
* Positive pregnancy test for girls post menarche or women of childbearing age.
* Severe psychiatric illness or mental deficiency making compliance to treatment unlikely and/or informed consent impossible.
* Any reason, at the investigator's discretion, that the participation of the patient in this protocol would not be in patient's best interest, or where the patient would be unable to adhere to the study requirements.

Primary outcomes:
measure: Safety in regards to engraftment, incidence and grade of acute and chronic graft-versus-host-disease, graft failure, infections, relapse, and non-relapse mortality post-haploidentical bone marrow transplantation.
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups
Secondary outcomes:
measure: Incidence of regimen-related organ toxicities
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Incidence of acute GvHD
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Severity of acute GvHD
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Incidence of chronic GvHD
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Extent of chronic GvHD
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Incidence of graft failure
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Infection risk
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Infection severity
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Overall patient survival
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Immune reconstitution following haploidentical BMT
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
measure: Incidence of bacterial, fungal and viral infections/reactivations
timeFrame: Change from baseline to 3 years. Interim analysis will be performed after cohort 3 and cohort 6 in Phase 1, and include preliminary evaluation of treatment and control groups]
Other outcomes:
Locations:
city: Tucson
country: United States
facility: The University of Arizona Cancer Center
state: Arizona
Study officials:
affiliation: The University of Arizona Cancer Center
name: Emmanuel Katsanis, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Katsanis E, Stea B, Kovacs K, Truscott L, Husnain M, Khurana S, Roe DJ, Simpson RJ. Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation. Transplant Cell Ther. 2022 Jul;28(7):390.e1-390.e10. doi: 10.1016/j.jtct.2022.04.015. Epub 2022 Apr 20.
citation: Katsanis E, Maher K, Roe DJ, Simpson RJ. Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. EJHaem. 2020 May 26;1(1):286-292. doi: 10.1002/jha2.20. eCollection 2020 Jul.
citation: Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2018 Oct;24(10):2034-2039. doi: 10.1016/j.bbmt.2018.06.007. Epub 2018 Jun 14.